# Purple Biotech LTD.: financial statements, quarterly

PPBT · Nasdaq · CIK 1614744 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ppbt.md) · [Financials](/companies/ppbt/financials.md) · [Filings](/companies/ppbt/filings.md) · [Insiders](/companies/ppbt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ppbt/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2014-12-31) | period not labelled (2015-12-31) | period not labelled (2016-12-31) | FY2017 (2017-12-31) | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [1.3](/filings/0001213900-18-002558.md) | [10.6](/filings/0001213900-19-004878.md) | [6.8](/filings/0001213900-20-007156.md) | [3.9](/filings/0001213900-21-015664.md) | [5.2](/filings/0001213900-22-011191.md) | [4.4](/filings/0001213900-23-017024.md) | [11.2](/filings/0001213900-24-020111.md) | [10.9](/filings/0001213900-25-022192.md) | [15.0](/filings/0001213900-26-031365.md) | [14.5](/filings/0001213900-26-031365.md) | [7.4](/filings/0001213900-26-031365.md) | [8.7](/filings/0001213900-26-031365.md) |
| Current assets | $m | not reported | not reported | [14.9](/filings/0001213900-18-002558.md) | [8.0](/filings/0001213900-19-004878.md) | [8.5](/filings/0001213900-20-007156.md) | [8.3](/filings/0001213900-21-015664.md) | [59.3](/filings/0001213900-21-015664.md) | [48.5](/filings/0001213900-23-017024.md) | [33.3](/filings/0001213900-24-020111.md) | [15.8](/filings/0001213900-25-022192.md) | [8.9](/filings/0001213900-26-031365.md) | [9.9](/filings/0001213900-26-031365.md) |
| Total assets | $m | not reported | not reported | [14.9](/filings/0001213900-18-002558.md) | [14.2](/filings/0001213900-19-004878.md) | [14.7](/filings/0001213900-20-007156.md) | [14.7](/filings/0001213900-21-015664.md) | [83.8](/filings/0001213900-22-011191.md) | [70.2](/filings/0001213900-23-017024.md) | [54.6](/filings/0001213900-24-020111.md) | [44.3](/filings/0001213900-25-022192.md) | [37.0](/filings/0001213900-26-031365.md) | [17.6](/filings/0001213900-26-031365.md) |
| Current liabilities | $m | not reported | not reported | [1.3](/filings/0001213900-18-002558.md) | [4.0](/filings/0001213900-19-004878.md) | [3.3](/filings/0001213900-20-007156.md) | [3.5](/filings/0001213900-21-015664.md) | [3.1](/filings/0001213900-22-011191.md) | [4.3](/filings/0001213900-23-017024.md) | [7.1](/filings/0001213900-24-020111.md) | [9.7](/filings/0001213900-25-022192.md) | [4.0](/filings/0001213900-26-031365.md) | [7.8](/filings/0001213900-26-031365.md) |
| Shareholders' equity | $m | [0.8](/filings/0001213900-20-007156.md) | [9.4](/filings/0001213900-20-007156.md) | [13.4](/filings/0001213900-18-002558.md) | [7.4](/filings/0001213900-19-004878.md) | [10.5](/filings/0001213900-20-007156.md) | [10.4](/filings/0001213900-21-015664.md) | [79.4](/filings/0001213900-22-011191.md) | [64.8](/filings/0001213900-23-017024.md) | [46.9](/filings/0001213900-24-020111.md) | [34.2](/filings/0001213900-25-022192.md) | [32.9](/filings/0001213900-26-031365.md) | [9.7](/filings/0001213900-26-031365.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent

Shares outstanding: 1,858,911,801 at 2025-12-31, from the cover of the [20-F filed 2026-03-19](/filings/0001213900-26-031365.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.